RTX (RTX) investor relations material

Executive summary

• Revenue for the first nine months of 2025/26 rose by 2% year-over-year to DKK 416 million, or 8.5% growth at constant currency, despite component shortages and production constraints limiting full demand conversion.

• Broad-based commercial momentum across all segments, with Healthcare and ProAudio showing strong growth and Enterprise impacted by supply challenges.

• Gross margin improved by 4.1 percentage points year-over-year to 54.8% for the nine-month period.

• EBITDA for the nine months reached DKK 30.1 million, up 35% year-over-year, driven by higher gross margin and growth in ProAudio and Healthcare segments.

• Strong order backlog and positive customer forecasts support continued growth.

Financial highlights

• Q3 2025/26 revenue rose 3% year-over-year to DKK 151 million; 9M revenue up 2% to DKK 416 million (8.5% at constant currencies).

• Gross margin improved to 53.3% in Q3 and 54.8% for 9M, driven by favorable segment/product mix and higher ProAudio and Healthcare share.

• 9M EBITDA: DKK 30.1 million (+35% YoY).

• EBIT for Q3 was DKK 6 million; 9M EBIT increased to DKK 8 million from DKK 2 million.

• Net profit for Q3 was DKK 4.4 million; 9M net profit was DKK 6.8 million.

Outlook and guidance

• Full-year revenue outlook raised to DKK 590–625 million (from DKK 575–625 million).

• Full-year EBITDA guidance increased to DKK 50–75 million (from DKK 35–65 million).

• Full-year EBIT guidance raised to DKK 20–45 million (from DKK 0–30 million).

• Outlook reflects strong order book, positive customer momentum, and ongoing supply constraints expected to persist into Q4.

• Ambition to achieve double-digit annual revenue growth and EBITDA margin above 15% by 2030.